Clinical characteristics of patients with early-stage NKTCL before and after PSM stratification by treatment
| . | RT alone . | CT alone . | . | RT with or without CT . | CT alone . | . |
|---|---|---|---|---|---|---|
| . | No. (%) . | No. (%) . | P . | No. (%) . | No. (%) . | P . |
| Before match | ||||||
| Total number | 253 | 170 | 1103 | 170 | ||
| Gender, male | 169 (66.8) | 121 (71.2) | .342 | 761 (69.0) | 121 (71.2) | .566 |
| Age, >60 y | 51 (20.2) | 28 (16.5) | .340 | 146 (13.2) | 28 (16.5) | .253 |
| B symptoms | 62 (24.5) | 80 (47.1) | <.001 | 429 (38.9) | 80 (47.1) | .043 |
| Elevated LDH | 58 (22.9) | 66 (38.8) | <.001 | 337 (30.6) | 66 (38.8) | .031 |
| ECOG ≥2 | 8 (3.2) | 21 (12.4) | <.001 | 50 (4.5) | 21 (12.4) | <.001 |
| UADT | 252 (99.6) | 163 (95.9) | .008 | 1097 (99.5) | 163 (95.9) | .001 |
| Stage II | 42 (16.6) | 61 (35.9) | <.001 | 265 (24.0) | 61 (35.9) | .001 |
| PTI | 100 (39.5) | 104 (61.2) | <.001 | 585 (53.0) | 104 (61.2) | .047 |
| After match | ||||||
| Total number | 107 | 107 | 158 | 158 | ||
| Gender, male | 77 (72.0) | 75 (70.1) | .763 | 119 (75.3) | 111 (70.3) | .312 |
| Age, >60 y | 16 (15.0) | 17 (15.9) | .850 | 28 (17.7) | 25 (15.8) | .651 |
| B symptoms | 38 (35.5) | 37 (34.6) | .886 | 85 (53.8) | 75 (47.5) | .261 |
| Elevated LDH | 33 (30.8) | 32 (29.9) | .882 | 60 (38.0) | 64 (40.5) | .645 |
| ECOG ≥2 | 3 (2.8) | 1 (0.9) | .621 | 12 (7.6) | 12 (7.6) | 1.000 |
| UADT | 106 (99.1) | 105 (98.1) | 1.000 | 154 (97.5) | 154 (97.5) | 1.000 |
| Stage II | 34 (31.8) | 35 (32.7) | .884 | 53 (33.5) | 56 (35.4) | .723 |
| PTI | 64 (59.8) | 64 (59.8) | 1.000 | 98 (63.0) | 101 (63.9) | .727 |
| . | RT alone . | CT alone . | . | RT with or without CT . | CT alone . | . |
|---|---|---|---|---|---|---|
| . | No. (%) . | No. (%) . | P . | No. (%) . | No. (%) . | P . |
| Before match | ||||||
| Total number | 253 | 170 | 1103 | 170 | ||
| Gender, male | 169 (66.8) | 121 (71.2) | .342 | 761 (69.0) | 121 (71.2) | .566 |
| Age, >60 y | 51 (20.2) | 28 (16.5) | .340 | 146 (13.2) | 28 (16.5) | .253 |
| B symptoms | 62 (24.5) | 80 (47.1) | <.001 | 429 (38.9) | 80 (47.1) | .043 |
| Elevated LDH | 58 (22.9) | 66 (38.8) | <.001 | 337 (30.6) | 66 (38.8) | .031 |
| ECOG ≥2 | 8 (3.2) | 21 (12.4) | <.001 | 50 (4.5) | 21 (12.4) | <.001 |
| UADT | 252 (99.6) | 163 (95.9) | .008 | 1097 (99.5) | 163 (95.9) | .001 |
| Stage II | 42 (16.6) | 61 (35.9) | <.001 | 265 (24.0) | 61 (35.9) | .001 |
| PTI | 100 (39.5) | 104 (61.2) | <.001 | 585 (53.0) | 104 (61.2) | .047 |
| After match | ||||||
| Total number | 107 | 107 | 158 | 158 | ||
| Gender, male | 77 (72.0) | 75 (70.1) | .763 | 119 (75.3) | 111 (70.3) | .312 |
| Age, >60 y | 16 (15.0) | 17 (15.9) | .850 | 28 (17.7) | 25 (15.8) | .651 |
| B symptoms | 38 (35.5) | 37 (34.6) | .886 | 85 (53.8) | 75 (47.5) | .261 |
| Elevated LDH | 33 (30.8) | 32 (29.9) | .882 | 60 (38.0) | 64 (40.5) | .645 |
| ECOG ≥2 | 3 (2.8) | 1 (0.9) | .621 | 12 (7.6) | 12 (7.6) | 1.000 |
| UADT | 106 (99.1) | 105 (98.1) | 1.000 | 154 (97.5) | 154 (97.5) | 1.000 |
| Stage II | 34 (31.8) | 35 (32.7) | .884 | 53 (33.5) | 56 (35.4) | .723 |
| PTI | 64 (59.8) | 64 (59.8) | 1.000 | 98 (63.0) | 101 (63.9) | .727 |